BioCentury
ARTICLE | Clinical News

Velcade bortezomib: Phase II; approved in U.S. for multiple myeloma (MM)

July 7, 2003 7:00 AM UTC

MLNM began a U.S. and U.K. open-label Phase II trial in about 152 patients. Johnson & Johnson (JNJ, New Brunswick, N.J.) is co-developing the compound for MM and other cancers. ...